secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031482
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024
---------------------------------------------------------------------------

- Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.
- Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.
- Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).
- ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/0000950170-24-031482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024031482/elvn-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer